PML down‐regulation in soft tissue sarcomas

To date, little is known concerning the promyelocytic leukemia gene (PML) status in tumors of different origin, and its expression has never been evaluated in soft tissue sarcoma. The aim of the present study is focused on the identification of differences in terms of PML protein expression between different types of soft tissue sarcoma and the corresponding normal surrounding tissue. PML protein expression has been assessed by immunohistochemistry in six different histologic types of soft tissue sarcoma (synovial sarcoma, myofibroblastic sarcoma, angiosarcoma, liposarcoma, pleomorphic sarcoma, and leiomyosarcoma) and in the corresponding normal surrounding tissue. PML resulted significantly down‐regulated in synovial sarcoma and in myofibroblastic sarcoma specimens. Also in angiosarcoma samples a significative difference in PML expression in comparison with normal specimens has been detected. Interestingly PML protein detection showed a different pattern of expression in the three liposarcoma histology types compared with corresponding nontumoral tissues. In particular PML protein resulted significantly down‐regulated in myxoid liposarcoma and in dedifferentiated liposarcoma. On the contrary no statistically significant difference was observed in pleomorphic liposarcoma compared to normal tissue specimens. Further investigations are needed to confirm these data and to assess the possible value of PML expression as a prognostic factor in these extremely aggressive diseases. J. Cell. Physiol. 224: 644–648, 2010. © 2010 Wiley‐Liss, Inc.

[1]  S. Morini,et al.  Promyelocytic leukemia (PML) gene expression is a prognostic factor in ampullary cancer patients. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Peter Dittrich,et al.  Dynamics of component exchange at PML nuclear bodies , 2008, Journal of Cell Science.

[3]  P. Salomoni,et al.  New insights into the role of PML in tumour suppression , 2008, Cell Research.

[4]  Jiri Bartek,et al.  An Oncogene-Induced DNA Damage Model for Cancer Development , 2008, Science.

[5]  J. Blay,et al.  Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Rugang Zhang,et al.  Downregulation of Wnt signaling is a trigger for formation of facultative heterochromatin and onset of cell senescence in primary human cells. , 2007, Molecular cell.

[7]  H. Lee,et al.  Loss of promyelocytic leukemia protein in human gastric cancers. , 2007, Cancer letters.

[8]  M. Lipinski,et al.  Definition of pRB- and p53-Dependent and -Independent Steps in HIRA/ASF1a-Mediated Formation of Senescence-Associated Heterochromatin Foci , 2007, Molecular and Cellular Biology.

[9]  P. Pandolfi,et al.  The promyelocytic leukemia protein functions as a negative regulator of IFN-γ signaling , 2006, Proceedings of the National Academy of Sciences.

[10]  Pier Paolo Pandolfi,et al.  The mechanisms of PML-nuclear body formation. , 2006, Molecular cell.

[11]  Rosa Bernardi,et al.  PML inhibits HIF-1α translation and neoangiogenesis through repression of mTOR , 2006, Nature.

[12]  P. Pandolfi,et al.  A CK2-Dependent Mechanism for Degradation of the PML Tumor Suppressor , 2006, Cell.

[13]  Jason A. Koutcher,et al.  Identification of a tumour suppressor network opposing nuclear Akt function , 2006, Nature.

[14]  P. Salomoni,et al.  Daxx: death or survival protein? , 2006, Trends in cell biology.

[15]  P. Pandolfi,et al.  The promyelocytic leukemia protein functions as a negative regulator of IFN-gamma signaling. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Rosa Bernardi,et al.  PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. , 2006, Nature.

[17]  P. Pandolfi,et al.  The promyelocytic leukaemia protein tumour suppressor functions as a transcriptional regulator of p63 , 2005, Oncogene.

[18]  Sara L. Tuttle,et al.  The promyelocytic leukemia protein PML regulates c-Jun function in response to DNA damage. , 2005, Blood.

[19]  P. Pandolfi,et al.  Cytoplasmic PML function in TGF-β signalling , 2004, Nature.

[20]  P. Pandolfi,et al.  Loss of the tumor suppressor PML in human cancers of multiple histologic origins. , 2004, Journal of the National Cancer Institute.

[21]  Pier Paolo Pandolfi,et al.  Cytoplasmic PML function in TGF-beta signalling. , 2004, Nature.

[22]  L. Latonen,et al.  Cellular stress and DNA damage invoke temporally distinct Mdm2, p53 and PML complexes and damage-specific nuclear relocalization , 2003, Journal of Cell Science.

[23]  T. Hofmann,et al.  PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains. , 2003, Cancer research.

[24]  Hyungtae Kim,et al.  PML-RARα Alleviates the Transcriptional Repression Mediated by Tumor Suppressor Rb* , 2001, The Journal of Biological Chemistry.

[25]  V. Lallemand-Breitenbach,et al.  Pathways of retinoic acid- or arsenic trioxide-induced PML/RARα catabolism, role of oncogene degradation in disease remission , 2001, Oncogene.

[26]  A. Kentsis,et al.  PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA , 2001, The EMBO journal.

[27]  P. Pearson,et al.  Atmospheric carbon dioxide concentrations over the past 60 million years , 2000, Nature.

[28]  Pier Paolo Pandolfi,et al.  PML regulates p53 acetylation and premature senescence induced by oncogenic Ras , 2000, Nature.

[29]  T. Pozzan,et al.  Cooperation between the RING+B1-B2 and coiled-coil domains of PML is necessary for its effects on cell survival , 1998, Oncogene.

[30]  S. Pileri,et al.  Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti-PML). , 1997, Blood.

[31]  H. Wanebo,et al.  Soft tissue sarcoma. , 1997, Medicine and health, Rhode Island.

[32]  J. Sobczak-Thépot,et al.  The PML growth-suppressor has an altered expression in human oncogenesis. , 1995, Oncogene.

[33]  K. Umesono,et al.  Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML , 1991, Cell.

[34]  Christine Chomienne,et al.  The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus , 1990, Nature.

[35]  J. Sinkovics,et al.  Chemotherapy of sarcomas with a combination of adriamycin and dimethyl triazeno imidazole carboxamide , 1972, Cancer.